

- **Name:** Taroh Satoh MD, PhD
 - **Current Position & Affiliation:** Associate Professor,
Palliative and Supportive Care Center
Osaka University Hospital
 - **Country:** Japan
-

• Educational Background:

- 1993: Graduated Hirosaki University School of Medicine

• Professional Experience:

- 1993-1998: Residency and Fellow at First Department of Internal Medicine at University Hospital Hirosaki University School of Medicine
- Dec 1998-Jul 2001: Case Western Reserve Univ. School of Medicine (USA), Dept. of Medicine, Div. of Hematology & Oncology (Research Scholar)
- Aug 2001-Jan 2003: Univ. of Colorado Health Science Center School of Medicine, Biochemistry and Mol. Genetics (Postdoctoral fellow)
- Feb 2003-Mar 2003: Fellow at First Department of Internal Medicine at University Hospital, Hirosaki University School of Medicine
- Apr 2003-Mar 2005: Instructor of Department of Medical Oncology, Kinki University School of Medicine,
- Apr 2005-Mar 2011: Assistant Professor of Department of Medical Oncology Kinki University Faculty of Medicine
- Apr 2011-Mar 2014: Associate Professor of Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine
- Apr 2014-: Professor of Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine
- Apr 2022-present: Associate Professor Vice President of Palliative and Supportive Care Center, Osaka University Hospital

• Professional Organizations:

- Japan Society of Internal Medicine
- Japanese Cancer Association
- Japanese Society of Clinical Oncology
- Japan Society for Medical Oncology
- Japanese Society of Gastroenterology
- Japan Lung Cancer Society American Association for Cancer Research
- American Society of Clinical Oncology
- European Society for Medical Oncology

• Main Scientific Publications:

1. Matsuyama J, Terazawa **Satoh T**. et al, Three-Year Outcomes of a Phase II Study of Perioperative Capecitabine Plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601). *Oncologist*. 2022 Apr 5;27(4):251-e304.
2. Kato A, Miyoshi N, **Satoh T**, et al A Phase II Study of Dose-reductive XELOX Plus Bevacizumab in Elderly or Vulnerable Patients With Metastatic Colorectal Cancer (MCSGO-1202). *Anticancer Res*. 2022 Apr;42(4):1859-1865. doi: 10.21873/anticancer.15662.
3. Nakamura Y, Okamoto W, **Satoh T**, et al Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy. *JCO Precis Oncol*. 2022 Feb;6: e2100383. doi:10.1200/PO.21.00383.
4. Makino T, Yamasaki M, **Satoh T**, et al Multicenter randomised trial of two versus three courses of preoperative cisplatin and fluorouracil plus docetaxel for locally advanced oesophageal squamous cell carcinoma. *Br J Cancer*. 2022 Feb 9. doi: 10.1038/s41416-022-01726-5.
5. Yoshikawa AK, Yamaguchi K, **Satoh T**, et al Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b study. *J Immunother Cancer*. 2022 Jan;10(1):e003518.
6. Imamura H, Matsuyama J, **Satoh T**, et al Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG). Effects of an oral elemental nutritional supplement in gastric cancer patients with adjuvant S-1 chemotherapy after gastrectomy: A multicenter, open-label, single-arm, prospective phase II study (OGSG1108) *Ann Gastroenterol Surg* 2021 Jul 16;5(6):776-784.
7. Shimokawa M, Hayashi T, **Satoh T**, et al Pooled analysis of combination antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with colorectal cancer treated with oxaliplatin-based chemotherapy of moderate emetic risk. *BMC Cancer* 2021 Oct 16;21(1): 1111. doi: 10.1186/s12885-021-08860-y.
8. Muro K, Kojima T, **Satoh T**, et al Second-line pembrolizumab versus chemotherapy in Japanese patients with advanced esophageal cancer: subgroup analysis from KEYNOTE-181. *Esophagus* 2021 Sep 30. doi: 10.1007/s10388-021-00877-3.
9. Kang YK, Morita S, **Satoh T**, et al Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study *Gastric Cancer*. 2021 Sep 4. doi: 10.1007/s10120-021-01230-4.
10. Kawase T, Imamura H, Satoh T. et al, Randomized phase II study of CPT-11 versus PTX versus each combination chemotherapy with S-1 for advanced gastric cancer that is refractory to S-1 or S-1 plus CDDP: OGSG0701 *nt J Clin Oncol*. 2021 Oct;26(10):1871-1880. doi: 10.1007/s10147-021-01984-y.
11. Nishizawa Y, Haraguchi N, **Satoh T**, et al Randomized phase II study of SOX+B-mab versus SOX+C-mab in patients with previously untreated recurrent advanced colorectal cancer with wild-type KRAS (MCSGO-1107 study) *BMC Cancer* 2021 Aug 23;21(1):947. doi: 10.1186/s12885-021-08690-y.